PMID- 23777385
OWN - NLM
STAT- MEDLINE
DCOM- 20140820
LR  - 20181202
IS  - 1097-9867 (Electronic)
IS  - 1083-7450 (Linking)
VI  - 19
IP  - 5
DP  - 2014 Aug
TI  - Release optimization of epidermal growth factor from PLGA microparticles.
PG  - 539-47
LID - 10.3109/10837450.2013.805776 [doi]
AB  - The objective of this study was to prepare poly lactic-co-glycolic acid 
      (PLGA)-based microparticles as potential carriers for recombinant human epidermal 
      growth factor (rhEGF). In order to optimize characteristic parameters of 
      protein-loaded microspheres, bovine serum albumin (BSA) was selected as the model 
      protein. To reduce burst release as a common problem of microspheres, a proper 
      alteration in the particle composition was used, such as addition of poly vinyl 
      alcohol and changes in initial drug loading. The effects of these parameters on 
      particle size, encapsulation efficiency and in vitro release kinetics of BSA in 
      PLGA microspheres were investigated using a Box-Behnken response surface 
      methodology. The biological activity of the released rhEGF was assessed using 
      human skin fibroblasts cell proliferation assay. The prepared rhEGF-loaded 
      microspheres had an average size of 6.44 +/- 2.45 microm, encapsulation efficiency of 
      97.04 +/- 1.13%, burst release of 13.06 +/- 1.35% and cumulative release of 22.56 +/- 
      2.41%. The proliferation of human skin fibroblast cells cultivated with rhEGF 
      releasate of microspheres was similar to that of pure rhEGF, indicating the 
      biological activity of released protein confirming the stability of rhEGF during 
      microsphere preparation. These results are in agreement with the purpose of our 
      study to prepare rhEGF-entrapped PLGA microparticles with optimized 
      characteristics.
FAU - Mirdailami, Omolbanin
AU  - Mirdailami O
AD  - Department of Pharmaceutics, Novel Drug Delivery Systems Lab .
FAU - Khoshayand, Mohammad Reza
AU  - Khoshayand MR
FAU - Soleimani, Masoud
AU  - Soleimani M
FAU - Dinarvand, Rassoul
AU  - Dinarvand R
FAU - Atyabi, Fatemeh
AU  - Atyabi F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130619
PL  - England
TA  - Pharm Dev Technol
JT  - Pharmaceutical development and technology
JID - 9610932
RN  - 0 (Drug Carriers)
RN  - 0 (Recombinant Proteins)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - IM
MH  - Animals
MH  - Cattle
MH  - Cell Line
MH  - Cell Proliferation/drug effects
MH  - Drug Carriers/*chemistry
MH  - Epidermal Growth Factor/*administration & dosage/pharmacology
MH  - Fibroblasts/cytology/drug effects
MH  - Humans
MH  - Lactic Acid/*chemistry
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Recombinant Proteins/administration & dosage/pharmacology
MH  - Serum Albumin, Bovine/administration & dosage
EDAT- 2013/06/20 06:00
MHDA- 2014/08/21 06:00
CRDT- 2013/06/20 06:00
PHST- 2013/06/20 06:00 [entrez]
PHST- 2013/06/20 06:00 [pubmed]
PHST- 2014/08/21 06:00 [medline]
AID - 10.3109/10837450.2013.805776 [doi]
PST - ppublish
SO  - Pharm Dev Technol. 2014 Aug;19(5):539-47. doi: 10.3109/10837450.2013.805776. Epub 
      2013 Jun 19.